Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NBRV vs. RAPT, KYTX, DRUG, PBYI, DMAC, IMAB, CYBN, TLSA, NVCT, and ENGNShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Rapt Therapeutics (RAPT), Kyverna Therapeutics (KYTX), Bright Minds Biosciences (DRUG), Puma Biotechnology (PBYI), DiaMedica Therapeutics (DMAC), I-Mab (IMAB), Cybin (CYBN), Tiziana Life Sciences (TLSA), Nuvectis Pharma (NVCT), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Rapt Therapeutics Kyverna Therapeutics Bright Minds Biosciences Puma Biotechnology DiaMedica Therapeutics I-Mab Cybin Tiziana Life Sciences Nuvectis Pharma enGene Nabriva Therapeutics (NASDAQ:NBRV) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation. Which has higher valuation & earnings, NBRV or RAPT? Nabriva Therapeutics has higher revenue and earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/ARapt Therapeutics$1.53M114.70-$129.87M-$19.20-0.55 Which has more risk & volatility, NBRV or RAPT? Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Is NBRV or RAPT more profitable? Rapt Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Rapt Therapeutics' return on equity of -81.47% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nabriva Therapeutics-148.11% -365.53% -135.81% Rapt Therapeutics N/A -81.47%-70.24% Do analysts prefer NBRV or RAPT? Rapt Therapeutics has a consensus target price of $19.80, suggesting a potential upside of 86.62%. Given Rapt Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapt Therapeutics is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rapt Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media favor NBRV or RAPT? In the previous week, Rapt Therapeutics had 12 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 12 mentions for Rapt Therapeutics and 0 mentions for Nabriva Therapeutics. Rapt Therapeutics' average media sentiment score of 0.38 beat Nabriva Therapeutics' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nabriva Therapeutics Neutral Rapt Therapeutics Neutral Do institutionals and insiders have more ownership in NBRV or RAPT? 0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 6.6% of Rapt Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryRapt Therapeutics beats Nabriva Therapeutics on 10 of the 14 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$763.73M$5.62B$9.29BDividend YieldN/A4.84%4.25%4.03%P/E Ratio0.001.1828.5719.58Price / SalesN/A25.52423.3293.40Price / CashN/A19.5636.0257.93Price / BookN/A6.918.135.54Net Income-$57.19M-$4.17M$3.24B$257.73M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RAPTRapt Therapeutics4.359 of 5 stars$10.85+24.4%$19.80+82.6%-62.9%$181.11M$1.53M-0.5780News CoverageAnalyst RevisionGap UpKYTXKyverna Therapeutics2.0033 of 5 stars$4.09-7.0%$18.50+352.0%-61.5%$178.84M$7.03M-1.2296Positive NewsDRUGBright Minds Biosciences2.3968 of 5 stars$25.35-1.2%$83.25+228.4%+2,288.2%$178.57MN/A-70.41N/APositive NewsPBYIPuma Biotechnology4.1989 of 5 stars$3.58+3.6%$7.00+95.8%-5.5%$177.43M$230.50M4.64200Gap UpDMACDiaMedica Therapeutics1.1814 of 5 stars$4.07+1.5%$8.00+96.6%+20.1%$174.52MN/A-6.3620IMABI-Mab2.8503 of 5 stars$2.13-0.5%$6.00+181.7%+28.8%$173.94M$3.89M0.00380Gap DownCYBNCybin2.47 of 5 stars$7.47flat$85.00+1,037.9%N/A$171.41MN/A-1.7050TLSATiziana Life Sciences1.3337 of 5 stars$1.47-1.0%N/A+82.6%$171.19MN/A0.008NVCTNuvectis Pharma3.3036 of 5 stars$8.27+0.6%$17.00+105.6%+24.5%$171.02MN/A-7.248Positive NewsENGNenGene2.809 of 5 stars$3.34-0.1%$23.29+598.2%-61.0%$170.16MN/A-2.0231 Related Companies and Tools Related Companies RAPT Alternatives KYTX Alternatives DRUG Alternatives PBYI Alternatives DMAC Alternatives IMAB Alternatives CYBN Alternatives TLSA Alternatives NVCT Alternatives ENGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBRV Stock Alerts